Statistics for A Phase II Study Assessing the Safety and Efficacy of ASP1650 in Male Patients with Relapsed Refractory Germ Cell Tumors
Total visits
| views | |
|---|---|
| A Phase II Study Assessing the Safety and Efficacy of ASP1650 in Male Patients with Relapsed Refractory Germ Cell Tumors | 3 |
Total visits per month
| views | |
|---|---|
| December 2024 | 0 |
| January 2025 | 0 |
| February 2025 | 0 |
| March 2025 | 0 |
| April 2025 | 0 |
| May 2025 | 0 |
| June 2025 | 0 |
File Visits
| views | |
|---|---|
| java.util.UUID:e7d983d9-b606-4798-a3fb-82f7811faef2 | 39 |
| java.util.UUID:0225e560-b015-4270-a4e6-a41a63c63d56 | 13 |
| Adra2022PhaseII-AAM.pdf | 10 |
| java.util.UUID:98df2953-179a-416d-9b13-9ba515b9d531 | 6 |
Top country views
| views | |
|---|---|
| United States | 3 |
Top city views
| views | |
|---|---|
| Indianapolis | 2 |
| Columbus | 1 |